• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

代谢功能障碍相关的脂肪变性肝小叶仿生模型在耦合微生理系统中诱导胰岛功能障碍。

A metabolic dysfunction-associated steatotic liver acinus biomimetic induces pancreatic islet dysfunction in a coupled microphysiology system.

机构信息

University of Pittsburgh Drug Discovery Institute, Pittsburgh, USA.

University of Pittsburgh Department of Bioengineering, Pittsburgh, USA.

出版信息

Commun Biol. 2024 Oct 14;7(1):1317. doi: 10.1038/s42003-024-07006-7.

DOI:10.1038/s42003-024-07006-7
PMID:39397070
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11471816/
Abstract

Preclinical and clinical studies suggest that lipid-induced hepatic insulin resistance is a primary defect that predisposes to dysfunction in islets, implicating a perturbed liver-pancreas axis underlying the comorbidity of T2DM and MASLD. To investigate this hypothesis, we developed a human biomimetic microphysiological system (MPS) coupling our vascularized liver acinus MPS (vLAMPS) with pancreatic islet MPS (PANIS) enabling MASLD progression and islet dysfunction to be assessed. The modular design of this system (vLAMPS-PANIS) allows intra-organ and inter-organ dysregulation to be deconvoluted. When compared to normal fasting (NF) conditions, under early metabolic syndrome (EMS) conditions, the standalone vLAMPS exhibited characteristics of early stage MASLD, while no significant differences were observed in the standalone PANIS. In contrast, with EMS, the coupled vLAMPS-PANIS exhibited a perturbed islet-specific secretome and a significantly dysregulated glucose stimulated insulin secretion response implicating direct signaling from the dysregulated liver acinus to the islets. Correlations between several pairs of a vLAMPS-derived and a PANIS-derived factors were significantly altered under EMS, as compared to NF conditions, mechanistically connecting MASLD and T2DM associated hepatic-factors with islet-derived GLP-1 synthesis and regulation. Since vLAMPS-PANIS is compatible with patient-specific iPSCs, this platform represents an important step towards addressing patient heterogeneity, identifying disease mechanisms, and advancing precision medicine.

摘要

临床前和临床研究表明,脂质诱导的肝胰岛素抵抗是导致胰岛功能障碍的主要缺陷,提示 T2DM 和 MASLD 合并症的基础是肝胰轴失调。为了验证这一假说,我们开发了一种人源仿生微生理系统(MPS),将我们的血管化肝小叶 MPS(vLAMPS)与胰岛 MPS(PANIS)相耦合,使 MASLD 进展和胰岛功能障碍能够得到评估。该系统(vLAMPS-PANIS)的模块化设计允许对器官内和器官间的失调进行解卷积。与正常空腹(NF)条件相比,在早期代谢综合征(EMS)条件下,独立的 vLAMPS 表现出早期 MASLD 的特征,而独立的 PANIS 则没有观察到显著差异。相比之下,在 EMS 条件下,耦合的 vLAMPS-PANIS 表现出胰岛特异性分泌组失调和葡萄糖刺激胰岛素分泌反应明显失调,提示从失调的肝小叶到胰岛的直接信号传递。与 NF 条件相比,在 EMS 条件下,几组源自 vLAMPS 和源自 PANIS 的因子之间的相关性发生了显著改变,从而将 MASLD 和与 T2DM 相关的肝因子与胰岛衍生的 GLP-1 合成和调节联系起来。由于 vLAMPS-PANIS 与患者特异性 iPSCs 兼容,该平台是朝着解决患者异质性、确定疾病机制和推进精准医学迈出的重要一步。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2522/11471816/924551a7d3e1/42003_2024_7006_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2522/11471816/924551a7d3e1/42003_2024_7006_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2522/11471816/924551a7d3e1/42003_2024_7006_Fig4_HTML.jpg

相似文献

1
A metabolic dysfunction-associated steatotic liver acinus biomimetic induces pancreatic islet dysfunction in a coupled microphysiology system.代谢功能障碍相关的脂肪变性肝小叶仿生模型在耦合微生理系统中诱导胰岛功能障碍。
Commun Biol. 2024 Oct 14;7(1):1317. doi: 10.1038/s42003-024-07006-7.
2
A metabolic-dysfunction associated steatotic liver acinus biomimetic induces pancreatic islet dysfunction in a coupled microphysiology system.一种与代谢功能障碍相关的脂肪变性肝腺泡仿生模型在耦合微生理学系统中诱导胰岛功能障碍。
bioRxiv. 2024 Apr 30:2024.04.22.590598. doi: 10.1101/2024.04.22.590598.
3
Comparison of wild-type and high-risk PNPLA3 variants in a human biomimetic liver microphysiology system for metabolic dysfunction-associated steatotic liver disease precision therapy.在用于代谢功能障碍相关脂肪性肝病精准治疗的人源化肝脏微生理系统中野生型和高危PNPLA3变体的比较
Front Cell Dev Biol. 2024 Sep 11;12:1423936. doi: 10.3389/fcell.2024.1423936. eCollection 2024.
4
Comparison of Wild-Type and High-risk PNPLA3 variants in a Human Biomimetic Liver Microphysiology System for Metabolic Dysfunction-associated Steatotic Liver Disease Precision Therapy.用于代谢功能障碍相关脂肪性肝病精准治疗的人源化肝脏微生理系统中野生型和高危型PNPLA3变体的比较。
bioRxiv. 2024 May 7:2024.04.22.590608. doi: 10.1101/2024.04.22.590608.
5
A glass-based, continuously zonated and vascularized human liver acinus microphysiological system (vLAMPS) designed for experimental modeling of diseases and ADME/TOX.用于疾病和 ADME/TOX 实验建模的基于玻璃的、连续分区和血管化的人类肝小叶微生理系统 (vLAMPS)
Lab Chip. 2018 Aug 21;18(17):2614-2631. doi: 10.1039/c8lc00418h.
6
Pump-Less, Recirculating Organ-on-Chip (rOoC) Platform to Model the Metabolic Crosstalk between Islets and Liver.无泵、循环式器官芯片(rOoC)平台,用于模拟胰岛和肝脏之间的代谢串扰。
Adv Healthc Mater. 2024 May;13(13):e2303785. doi: 10.1002/adhm.202303785. Epub 2024 Feb 9.
7
The LIDPAD Mouse Model Captures the Multisystem Interactions and Extrahepatic Complications in MASLD.LIDPAD 小鼠模型捕获了 MASLD 中的多系统相互作用和肝外并发症。
Adv Sci (Weinh). 2024 Sep;11(35):e2404326. doi: 10.1002/advs.202404326. Epub 2024 Jul 1.
8
Dysglycemia and liver lipid content determine the relationship of insulin resistance with hepatic OXPHOS capacity in obesity.血糖异常和肝脏脂质含量决定了肥胖症中胰岛素抵抗与肝脏氧化磷酸化能力之间的关系。
J Hepatol. 2025 Mar;82(3):417-426. doi: 10.1016/j.jhep.2024.08.012. Epub 2024 Aug 31.
9
Novel translational mouse models of metabolic dysfunction-associated steatotic liver disease comparable to human MASLD with severe obesity.与伴有严重肥胖的人类代谢功能障碍相关脂肪性肝病(MASLD)可比的新型代谢功能障碍相关脂肪性肝病的转化小鼠模型。
Mol Metab. 2025 Mar;93:102104. doi: 10.1016/j.molmet.2025.102104. Epub 2025 Jan 22.
10
Postpartum development of metabolic dysfunction-associated steatotic liver disease in a lean mouse model of gestational diabetes mellitus.妊娠糖尿病瘦鼠模型中代谢功能障碍相关脂肪性肝病的产后发病情况。
Sci Rep. 2024 Jun 25;14(1):14621. doi: 10.1038/s41598-024-65239-2.

引用本文的文献

1
Integrated Patient Digital and Biomimetic Twins for Precision Medicine: A Perspective.用于精准医学的综合患者数字双胞胎和仿生双胞胎:一种观点
Semin Liver Dis. 2025 Jul 23. doi: 10.1055/a-2649-1560.
2
In Vitro Modeling of Interorgan Crosstalk: Multi-Organ-on-a-Chip for Studying Cardiovascular-Kidney-Metabolic Syndrome.器官间串扰的体外建模:用于研究心血管-肾脏-代谢综合征的多器官芯片
Circ Res. 2025 May 23;136(11):1476-1493. doi: 10.1161/CIRCRESAHA.125.325497. Epub 2025 May 22.
3
Validation of microphysiological systems for interpreting patient heterogeneity requires robust reproducibility analytics and experimental metadata.

本文引用的文献

1
Comparison of wild-type and high-risk PNPLA3 variants in a human biomimetic liver microphysiology system for metabolic dysfunction-associated steatotic liver disease precision therapy.在用于代谢功能障碍相关脂肪性肝病精准治疗的人源化肝脏微生理系统中野生型和高危PNPLA3变体的比较
Front Cell Dev Biol. 2024 Sep 11;12:1423936. doi: 10.3389/fcell.2024.1423936. eCollection 2024.
2
Microphysiological pancreas-on-chip platform with integrated sensors to model endocrine function and metabolism.微生理胰岛芯片平台,集成传感器,用于模拟内分泌功能和代谢。
Lab Chip. 2024 Mar 26;24(7):2080-2093. doi: 10.1039/d3lc00838j.
3
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.
验证用于解释患者异质性的微生理系统需要强大的可重复性分析和实验元数据。
Cell Rep Methods. 2025 Apr 21;5(4):101028. doi: 10.1016/j.crmeth.2025.101028. Epub 2025 Apr 14.
一项评估 Resmetirom 治疗伴有肝纤维化的 NASH 的 3 期随机对照试验。
N Engl J Med. 2024 Feb 8;390(6):497-509. doi: 10.1056/NEJMoa2309000.
4
Hepatic glucose metabolism in the steatotic liver.脂肪变性肝脏中的肝葡萄糖代谢
Nat Rev Gastroenterol Hepatol. 2024 May;21(5):319-334. doi: 10.1038/s41575-023-00888-8. Epub 2024 Feb 2.
5
Pump-Less, Recirculating Organ-on-Chip (rOoC) Platform to Model the Metabolic Crosstalk between Islets and Liver.无泵、循环式器官芯片(rOoC)平台,用于模拟胰岛和肝脏之间的代谢串扰。
Adv Healthc Mater. 2024 May;13(13):e2303785. doi: 10.1002/adhm.202303785. Epub 2024 Feb 9.
6
A Novel Milli-fluidic Liver Tissue Chip with Continuous Recirculation for Predictive Pharmacokinetics Applications.一种新型毫流控肝组织芯片,具有连续循环功能,可用于预测药代动力学应用。
AAPS J. 2023 Oct 27;25(6):102. doi: 10.1208/s12248-023-00870-x.
7
Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: Screening, Diagnosis, and Treatment.2型糖尿病患者的非酒精性脂肪性肝病:筛查、诊断与治疗
J Clin Med. 2023 Aug 27;12(17):5597. doi: 10.3390/jcm12175597.
8
A Pillar and Perfusion Plate Platform for Robust Human Organoid Culture and Analysis.用于稳健的人类类器官培养和分析的支柱和灌注板平台。
Adv Healthc Mater. 2024 Aug;13(21):e2302502. doi: 10.1002/adhm.202302502. Epub 2023 Sep 10.
9
Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach.非酒精性脂肪性肝炎的抗纤维化治疗:以人为中心方法的时代。
Nat Rev Gastroenterol Hepatol. 2023 Oct;20(10):679-688. doi: 10.1038/s41575-023-00796-x. Epub 2023 Jun 2.
10
FFA-Fetuin-A regulates DPP-IV expression in pancreatic beta cells through TLR4-NFkB pathway.胎球蛋白A通过Toll样受体4-核因子κB途径调节胰岛β细胞中二肽基肽酶-4的表达。
Biochem Biophys Res Commun. 2023 Mar 5;647:55-61. doi: 10.1016/j.bbrc.2023.01.070. Epub 2023 Jan 23.